UPDATE: June 3, 2018, PRASM announced via Twitter it has closed its public sale.
Ahead of a pending Initial Coin Offering, Korea-based PRASM has announced new Memoranda of Understanding with multiple organizations in the healthcare sector.
The company’s aim is to establish a blockchain-based bioinformatics network in which users upload their biological data in exchange for tokens. PRASM says that by offering decentralized bioinformatics through its platform, it can help other companies offering healthcare services to tailor their offerings based on users’ needs, which in turn will deliver enhanced solutions to individuals who have submitted their information. The tokens they receive as compensation, meanwhile, can be used to purchase those specialized products and services, or sold on a cryptocurrency exchange.
PRASM’s new MOUs show that companies are starting to get interested. CL143 Private MEDI-Aging Center has signed on “as a business stakeholder,” according to a statement announcing the agreements; and the Ankylosing Spondylitis Federation has become a partner as part of its search for a cure for that form of arthritis. A third MOU, with Kazakhstan’s MyPartners organization, is aimed at encouraging “medical tourism in Central Asia,” PRASM says.
Other existing PRASM partners include Korea-based Oracle Medical Group, Malaysia’s Klinik Mediskin, Pilates SantaFe, and NOVU Medical Aesthetic Clinic.
PRASM’s ICO is slated for Q3, with the company planning to issue 2 billion PRASM tokens at a starting price of 1 ETH.
June 1, 2018 – by Alex Perala